newsfilter
← Latest News
GlobeNewswire·

Selecta Biosciences to Participate at the Guggenheim I&I Spotlight Series – Treg-based Therapies Conference

WATERTOWN, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies